Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107362 | 0.95 | ADAM17 (0.86) | ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL7111909 | 0.93 | ADAM17 (0.91) | ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL7110399 | 0.93 | ADAM17 (0.91) | ADAM17MMP13 | |
| SCHEMBL7106794 | 0.88 | ADAM17 (1.00) | ADAM17MMP13 | |
| SCHEMBL7107375 | 0.88 | ADAM17 (1.00) | ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL7110992 | 0.87 | ADAM17 (0.72) | ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL7110514 | 0.86 | ADAM17 (0.91) | ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL7110121 | 0.85 | ADAM17 (0.91) | ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL7112102 | 0.85 | ADAM17 (0.91) | ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL7111686 | 0.85 | ADAM17 (0.80) | ADAM17MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642255-B2 | Substituted carbocyclic or heterocyclic hydroxamic acid derivatives, e.g., (3R,4S)-N-hydroxy-1-methyl-3-(((4-((2-methyl-4 -quinolinyl)methoxylphenyl)sulfonyl)methyl)-4-piperidinecarboxamide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030087890-A1 | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087890-A1 | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | MMP1, MMP8, MMP9 | ADAM17 19/4885MMP13 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.